Results
NSCLC
NON-SMALL CELL LUNG CANCER, MAY, NSCLC
Between August 08, 2017 and December 09, 2019 a total of 40 patients were enrolled in the study. The primary analysis cutoff date was 25 May 2020 and the final cutoff date was 05 August 2020. At the time of data cutoff, no patients remained in study. In the dose-escalation part (module 1, part A) 24 patients were included in 5 dose levels: 100 mg BID, 200 mg BID, 400 mg BID, 250 mg BID, and 350 mg BID (Patient characteristics per cohort.Abbreviations: BID, twice daily, GCN, gene copy number, GI, gastrointestinal, METex14, MET exon 14 skipping mutation, METamp, MET amplification, NSCLC, non-small cell lung cancer.Overview of study design and patient inclusion. Dose-escalation was performed in Module 1, Part A. Cohort expansion in MET positive subgroups was performed in Module 1, Part B and Module 2, Part A. BID, twice daily, EGFR TKI, epidermal growth factor receptor tyrosine kinase inhibitor, METex14, MET exon 14 skipping mutation, NSCLC, non-small cell lung cancer.